Some of the biotech companies thriving in the First State include:
Incyte – A drug discovery and development company focusing on oncology. They began their drug discovery and development activities in early 2002. In late 2011, they received their first US Food and Drug Administration approval for Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor.
Adesis – A Contract Research Organization supporting the pharmaceutical, chemical, biomaterials, and catalyst industries. They provide expertise in custom synthesis, research and development, and specialty manufacturing.
W. L. Gore & Associates – W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 10,500 Associates and a strong, team-oriented culture, Gore generates annual revenues of $3.7 billion. gore.com
Prelude Therapeutics – A privately held, clinical-stage biopharmaceutical company designing and developing a pipeline of novel, orally bioavailable, small-molecule therapies that target key drivers of cancer cell growth, survival, and resistance.
Agilent – A leader in life sciences, diagnostics, and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications, and expertise.
Future of Biotech in Delaware
Biotech IS the future of Delaware. From biotech startups and agricultural biotech to research organizations supporting innovation in pharmaceuticals, biomaterials and catalyst industries, Delaware’s vibrant science economy is growing.
Well connected roads, and efficient transportation system and strong legislation that protects intellectual property, have, among other factors, played and continue to play a vital role in influencing biotech companies to choose Delaware.
What works over and above everything else for the biotechnology industry in Delaware is the fact that the First State has a strategic location in the center of the Innovation Corridor (from Washington to New York) and it does not compete in this field with the neighboring states, rather, they all work together as a part of the same region. Added to this are the very experienced ‘retired’ scientists who, with their vast knowledge in biotechnology, assist the firms in tiding overall problems and providing answers to difficult questions.
Delaware Innovation Space
Innovation in Delaware is happening every day in the biotechnology industry. Fueling that innovation is the Delaware Innovation Space launched in 2017 through a partnership between DuPont, the University of Delaware and the State of Delaware. Designed to accelerate science startups in Delaware, this multi-dimensional, resource-rich entrepreneurial science incubator includes state-of-the-art laboratories, business development resources and a group of people with top-notch expertise.
Why Delaware for Your Biotech Company
Delaware is a great place for both existing and emerging biotech companies. Biotechnology is a massive industrial hub and comprises of several areas like biopharmaceuticals, bio-services, bio-agriculture, bioindustry, and bio-IT. The First State contributes to and helps biotechnology companies flourish.
- Since 2014, the number of bioscience and biopharmaceutical entities in Delaware has gone up by around 33%.
- $61 million has been the amount of venture capital investments in the state’s bioscience companies since 2014.
- Among the 50 states, Delaware ranks 3rd in terms of bioscience-related patents per capita between 2014-17.
- 8,000 individuals are employed in Delaware’s bioscience industry with opportunities continuing to rise.
There are a lot of opportunities for biotech businesses in the First State as Delaware’s biotechnology capabilities continue to grow and attract businesses and talent worldwide.
“Delaware has a uniquely expansive array of bioscience businesses. Unlike other states, Delaware’s strength is its focus on innovation and its rich diversity of bioscience companies, including precision instrumentation, consumables, recombinant proteins, monoclonal antibodies, contract research organizations, and contract manufacturing organizations.” – Helen Stimson, CEO and President of the Delaware BioScience Association